

John Harrison

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11107823/john-harrison-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

2,062
citations

16
h-index

31
g-index

31
ext. papers

2,323
ext. citations

4.4
avg, IF

4.01
L-index

#	Paper	IF	Citations
31	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2008 , 7, 779-86	24.1	577
30	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. <i>Journal of Alzheimers Disease</i> , 2010 , 20, 509-16	4.3	306
29	Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. <i>Journal of Alzheimers Disease</i> , 2012 , 31, 225-36	4.3	202
28	Synaesthesia: prevalence and familiarity. <i>Perception</i> , 1996 , 25, 1073-9	1.2	178
27	Coloured speech perception: is synaesthesia what happens when modularity breaks down?. <i>Perception</i> , 1993 , 22, 419-26	1.2	175
26	A neuropsychological test battery for use in Alzheimer disease clinical trials. <i>Archives of Neurology</i> , 2007 , 64, 1323-9		151
25	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 873-881	4.6	63
24	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. <i>Alzheimers and Dementia</i> , 2017 , 13, 186-195	1.2	61
23	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimers Research and Therapy</i> , 2018 , 10, 107	9	48
22	Minimal cognitive impairment in UK HIV-positive men who have sex with men: effect of case definitions and comparison with the general population and HIV-negative men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 67, 120-7	3.1	47
21	Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. <i>Journal of Alzheimers Disease</i> , 2015 , 44, 471-80	4.3	40
20	A randomized placebo controlled trial of vitamin B supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B. <i>Clinical Nutrition</i> , 2017 , 36, 1509-1515	5.9	33
19	A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients. <i>Clinical Nutrition</i> , 2020 , 39, 2399-2405	5.9	24
18	A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 130-138	6	22
17	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017 , 222, 14-20	6.6	20
16	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. <i>Nature Aging</i> , 2021 , 1, 521-534		17
15	Measuring the mind: assessing cognitive change in clinical drug trials. <i>Expert Review of Clinical Pharmacology</i> , 2008 , 1, 471-3	3.8	14

14	Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2014 , 3, 158-69	2.5	13
13	Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB. <i>Clinical Neuropsychologist</i> , 2014 , 28, 252-68	4.4	12
12	Synaesthesia: An Account of Coloured Hearing. <i>Leonardo</i> , 1994 , 27, 343	0.1	12
11	A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test-retest reliability and feasibility. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 153-160	5.2	9
10	Cognitive approaches to early Alzheimer's disease diagnosis. <i>Medical Clinics of North America</i> , 2013 , 97, 425-38	7	9
9	Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it). <i>Scandinavian Journal of Pain</i> , 2017 , 15, 62-67	1.9	8
8	Synaesthesia: reconciling the subjective with the objective. <i>Endeavour</i> , 1995 , 19, 157-60	0.5	8
7	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2018 , 238, 228-232	6.6	6
6	Acquired and inherited forms of cross-modal correspondence. <i>Neurocase</i> , 1996 , 2, 245-249	0.8	5
5	Synaesthesia 2006 ,		1
4	Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. <i>Drug Discovery Today</i> , 2021 , 26, 1330-1336	8.8	1
3	Acquired and inherited forms of cross-modal correspondence. <i>Neurocase</i> , 1996 , 2, 245-249	0.8	
2	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol.. <i>BMJ Open</i> , 2022 , 12, e052250	3	
1	The Use and Development of Clinical Measures of Alzheimer's Disease Trials 2022 , 281-291		